SCHEMBL14350

SCHEMBL14350

NCc1ccc(-n2cc3cc(-c4ccc(S(=O)(=O)N(CCCN5CCOCC5)C5CCNCC5)cc4)[nH]c3nc2=O)cc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
DRD2 P14416 5/20 0.33
HTR2A P28223 5/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.32
EZH2 Q15910 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
VCP P55072 1/20 0.32
EP300 Q09472 1/20 0.32
HIF1A Q16665 1/20 0.32
TBK1 Q9UHD2 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14352 0.93 SLC6A2 (0.35) SLC6A2SLC6A4SLC6A3KCNH2DRD2
SCHEMBL12062022 0.92 SLC6A2 (0.35) CSF1RSLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL13893 0.90 SLC6A2 (0.38) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14519 0.89 CSF1R (0.33) CSF1RSLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12061894 0.86 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14428 0.86 KCNH2 (0.35) SLC6A2SLC6A4SLC6A3KCNH2ALDH1A1
SCHEMBL14450 0.86 SLC6A2 (0.34) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL13624 0.86 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14356 0.85 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL13941 0.85 SLC6A4 (0.36) SLC6A2SLC6A4SLC6A3KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT CSF1R 2254/4885SLC6A2 3776/4885SLC6A4 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.